Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?
作者信息
Graham David Y, Lu Hong, Shiotani Akiko
机构信息
Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, USA.
GI Division, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institution of Digestive Disease, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai, People's Republic of China.
出版信息
Saudi J Gastroenterol. 2017 Sep-Oct;23(5):265-267. doi: 10.4103/sjg.SJG_292_17.
Abstract
摘要
相似文献
1
Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?优化的质子泵抑制剂联合阿莫西林治疗失败：现在该怎么办？
Saudi J Gastroenterol. 2017 Sep-Oct;23(5):265-267. doi: 10.4103/sjg.SJG_292_17.
2
Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori.阿莫西林、克拉霉素和沃克（vonoprazan）三联疗法治疗幽门螺杆菌引起的多形红斑。
J Dermatol. 2016 Mar;43(3):340-1. doi: 10.1111/1346-8138.13187. Epub 2015 Oct 28.
3
Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy.比较研究：沃克帕唑与质子泵抑制剂在根除治疗中的应用
World J Gastroenterol. 2017 Jan 28;23(4):668-675. doi: 10.3748/wjg.v23.i4.668.
4
Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy.
Dig Liver Dis. 2016 Jun;48(6):688-9. doi: 10.1016/j.dld.2016.02.021. Epub 2016 Mar 2.
5
Talicia - a 3-drug combination for Helicobacter pylori infection.塔利察——一种用于治疗幽门螺杆菌感染的三联药物组合。
Med Lett Drugs Ther. 2020 Jun 1;62(1599):83-85.
6
High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.14 天三联疗法为基础的含铋四联疗法对初始幽门螺杆菌根除的高疗效。
Helicobacter. 2010 Jun;15(3):233-8. doi: 10.1111/j.1523-5378.2010.00758.x.
7
Treatment of Helicobacter pylori.幽门螺杆菌治疗。
Curr Opin Gastroenterol. 2019 Nov;35(6):544-550. doi: 10.1097/MOG.0000000000000578.
8
Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.在中国，优化后的高剂量阿莫西林-质子泵抑制剂双重疗法未能实现高治愈率。
Saudi J Gastroenterol. 2017 Sep-Oct;23(5):275-280. doi: 10.4103/sjg.SJG_91_17.
9
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.基于沃克帕唑的三联疗法根除幽门螺杆菌的疗效：一项多中心研究及文献综述
Dig Dis Sci. 2017 Nov;62(11):3069-3076. doi: 10.1007/s10620-017-4664-1. Epub 2017 Jun 29.
10
Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.马斯特里赫特II治疗方案及不同质子泵抑制剂根除幽门螺杆菌的疗效
World J Gastroenterol. 2004 Jun 1;10(11):1656-8. doi: 10.3748/wjg.v10.i11.1656.
引用本文的文献
1
First-Line Levofloxacin-Based Triple Therapy Versus Standard Bismuth-Based Quadruple Therapy for Eradication in Saudi Arabia: A Retrospective Single-Center Study.沙特阿拉伯基于左氧氟沙星的一线三联疗法与标准铋剂四联疗法根除幽门螺杆菌的回顾性单中心研究
Health Sci Rep. 2025 Feb 5;8(2):e70432. doi: 10.1002/hsr2.70432. eCollection 2025 Feb.
2
Vonoprazan-amoxicillin dual therapy for eradication: A systematic review and meta-analysis of randomized controlled trials.Vonoprazan-阿莫西林双联疗法根除治疗：一项随机对照试验的系统评价和荟萃分析。
Saudi J Gastroenterol. 2023 Nov-Dec;29(6):347-357. doi: 10.4103/sjg.sjg_153_23.
3
High-dose dual therapy bismuth-containing quadruple therapy for eradication: a systematic review and meta-analysis with trial sequential analysis.高剂量双重疗法铋剂四联疗法根除幽门螺杆菌：一项采用试验序贯分析的系统评价和Meta分析
Therap Adv Gastroenterol. 2023 Jan 10;16:17562848221147756. doi: 10.1177/17562848221147756. eCollection 2023.
4
Current guidelines for treatment in East Asia 2022: Differences among China, Japan, and South Korea.《2022年东亚治疗指南：中国、日本和韩国之间的差异》
World J Clin Cases. 2022 Jul 6;10(19):6349-6359. doi: 10.12998/wjcc.v10.i19.6349.
5
diagnosis and therapy in the era of antimicrobial stewardship.抗菌药物管理时代的诊断与治疗
Therap Adv Gastroenterol. 2021 Dec 21;14:17562848211064080. doi: 10.1177/17562848211064080. eCollection 2021.
6
Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections.益生菌作为对抗幽门螺杆菌胃部感染的活体微生物战士。
BMC Gastroenterol. 2021 Oct 20;21(1):388. doi: 10.1186/s12876-021-01977-1.
7
Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study.在坦桑尼亚西北部的一家三级医院就诊的 H. pylori 感染患者中三联疗法治疗失败的预测因素：一项前瞻性研究。
BMC Infect Dis. 2019 May 21;19(1):447. doi: 10.1186/s12879-019-4085-1.
8
Role of Probiotics in Eradication: Lessons from a Study of Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor.益生菌在根除治疗中的作用：来自对DSM 17938和ATCC PTA 6475菌株（Gastrus®）及质子泵抑制剂研究的经验教训
Can J Infect Dis Med Microbiol. 2019 Apr 1;2019:3409820. doi: 10.1155/2019/3409820. eCollection 2019.
9
Current and Future Treatment of Helicobacter pylori Infections.当前和未来的幽门螺杆菌感染治疗。
Adv Exp Med Biol. 2019;1149:211-225. doi: 10.1007/5584_2019_367.
10
Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI.质子泵抑制剂的相对效力、幽门螺杆菌治疗的治愈率以及双倍剂量 PPI 的意义。
Helicobacter. 2019 Feb;24(1):e12554. doi: 10.1111/hel.12554. Epub 2018 Nov 15.
本文引用的文献
1
Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China.在中国，优化后的高剂量阿莫西林-质子泵抑制剂双重疗法未能实现高治愈率。
Saudi J Gastroenterol. 2017 Sep-Oct;23(5):275-280. doi: 10.4103/sjg.SJG_91_17.
2
Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis.大剂量双重疗法用于幽门螺杆菌补救治疗的疗效与安全性：一项系统评价和荟萃分析
J Dig Dis. 2016 Dec;17(12):811-819. doi: 10.1111/1751-2980.12432.
3
Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.使用质子泵抑制剂或钾离子竞争性酸阻滞剂根除幽门螺杆菌：克拉霉素耐药性的影响
Dig Dis Sci. 2016 Nov;61(11):3215-3220. doi: 10.1007/s10620-016-4305-0. Epub 2016 Sep 22.
4
Role of bismuth in improving Helicobacter pylori eradication with triple therapy.铋在三联疗法提高幽门螺杆菌根除率中的作用。
Gut. 2016 May;65(5):870-8. doi: 10.1136/gutjnl-2015-311019. Epub 2016 Feb 4.
5
High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.高剂量双重疗法治疗幽门螺杆菌感染优于标准一线治疗或挽救治疗。
Clin Gastroenterol Hepatol. 2015 May;13(5):895-905.e5. doi: 10.1016/j.cgh.2014.10.036. Epub 2014 Nov 14.
6
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.日本人群中质子泵抑制剂标准剂量的酸抑制作用与CYP2C19基因型的比较。
Eur J Clin Pharmacol. 2014 Sep;70(9):1073-8. doi: 10.1007/s00228-014-1713-y. Epub 2014 Jul 6.
7
The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.酸度变化对幽门螺杆菌生长和氨苄西林杀菌效果的影响。
Aliment Pharmacol Ther. 2012 Nov;36(10):972-9. doi: 10.1111/apt.12059. Epub 2012 Sep 25.
8
Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study.将双联阿莫西林加奥美拉唑根除幽门螺杆菌的疗程延长至 6 周：一项初步研究。
J Gastroenterol Hepatol. 2012 Jan;27(1):59-61. doi: 10.1111/j.1440-1746.2011.06876.x.
9
Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.奥美拉唑剂量和细胞色素 P450 2C19 基因型在接受奥美拉唑-阿莫西林双联疗法根除幽门螺杆菌治疗的患者中的作用。
Pharmacotherapy. 2011 Mar;31(3):227-38. doi: 10.1592/phco.31.3.227.
10
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.幽门螺杆菌感染根除治疗的药理学方面。
Gastroenterol Clin North Am. 2010 Sep;39(3):465-80. doi: 10.1016/j.gtc.2010.08.007.
Zotero 插件